Polyrizon Ltd. (NASDAQ:PLRZ – Get Free Report) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 94,216 shares, an increase of 48.8% from the July 30th total of 63,322 shares. Based on an average daily volume of 59,143 shares, the days-to-cover ratio is currently 1.6 days. Currently, 4.5% of the shares of the stock are sold short.
Analysts Set New Price Targets
A number of brokerages have recently commented on PLRZ. Wall Street Zen upgraded shares of Polyrizon from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. Weiss Ratings upgraded shares of Polyrizon from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Polyrizon currently has an average rating of “Sell”.
View Our Latest Analysis on PLRZ
Institutional Trading of Polyrizon
Polyrizon Price Performance
Shares of PLRZ stock traded down $0.60 during trading hours on Tuesday, reaching $13.91. The company had a trading volume of 162,713 shares, compared to its average volume of 63,364. Polyrizon has a 12-month low of $2.88 and a 12-month high of $18.20. The stock has a fifty day moving average of $12.38 and a 200-day moving average of $13.11.
About Polyrizon
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Further Reading
- Five stocks we like better than Polyrizon
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
- Analysts See Major Upside for This Top-10 Performing S&P 500 Stock
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
